Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 8Phase 1/2 3Phase 3 2

Status

Unknown 2Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 32Other hematologic neoplasm 8Genitourinary 8Breast 5Sarcoma 4Thoracic 3Myeloid 3Dermatologic 3CNS 3Tumor-Agnostic 2Plasma cell 2Lymphoid 2Gynecologic 2Other solid neoplasm 1

Conditions

Melanoma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Sorafenib × Dermatologic × Clear all
NCT00474929 2019-08-20

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
103 enrolled 12 charts
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT00538005 2014-01-10

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
54 enrolled
Dermatologic

Melanoma

NCT00811759 2010-10-07

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡